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Composite Mesenchymal Stromal Cell Islets:
Implications for Transplantation via the Clinically
Preferred Intraportal Route
Chloe L. Rackham, PhD,1 Paramjeet K. Dhadda, PhD,1 Sian J.S. Simpson, BSc,1 Mahdieh Godazgar, BSc,1
Aileen J.F. King, PhD,1 and Peter M. Jones, PhD1
Cotransplantation of islets with mesenchymal stromalcells (MSCs) has been shown to improve islet trans-
plantation outcome. Improved glycemia in graft recipients
have been attributed to superior islet revascularization,main-
tenance of islet organization and morphology, and a multi-
tude of immunomodulatory mechanisms. These effects are
mediated by a vast array of soluble trophic MSC-derived
factors and extracellular matrix production, and/or direct
cell-cell contact mechanisms. Most of these studies have
used experimental transplantation sites, such as the kidney,
to facilitate the colocalization of large numbers ofMSCswith
the islet graft. However, there are notable disparities with the
clinically preferred intraportal route which have implications
for colocalization of the islets and MSCs. Thus, because of
the differences in their size, islets lodge in small vessels of
the hepatic microcirculation, whereas the smaller MSCs will
most likely engraft in other sites, such as the microvascula-
ture of the lungs.1
An alternative method to ensure colocalization of the MSCs
with islets posttransplantation is to form composite MSC islets
in vitro,2,3 before transplantation. This approach has demon-
strated beneficial effects on islet revascularization and reduc-
tions in graft lymphocyte infiltration.3 We aimed to determine
whether compositeMSC islets transplanted to the clinically pre-
ferred intraportal site improve glycemia in diabetic mice. Com-
posite MSC islets were formed by suspension coculture and
visualized using aNikon Biostation. Islet insulin secretory func-
tion in vitro was assessed by static secretion assays.4,5
Intraportal syngeneic islet transplantations (C57Bl/6mice)were
used4 to assess the in vivo function of MSC islet composites.
Mesenchymal stromal cells adhered to the surface of islets
in a randommanner and appeared to penetrate the islet struc-
ture within 8 hours (75 islets: 200 000MSCs [Figures 1A and
B]). There was limited interaction ofMSCs with islets at lower
MSC doses (20 000). We demonstrated an MSC dose-
dependent potentiation of glucose-stimulated insulin secre-
tion when islets were precultured with MSCs in suspension
coculture to form composites (Figure 1C). The majority
of MSCs at both doses remained in suspension and did
not adhere to cocultured islets, so transplantingMSC islet
composites greatly reduced the dose of MSCs delivered in
the graft when compared with cotransplanting islets and
MSCs at the renal subcapsular site. Average blood glucose
concentrations were comparable between transplant groups
for the first 3 weeks posttransplantation and were lower
at 4 weeks posttransplantation in recipients of MSC islet
composites (Figure 1D).
Our current findings demonstrate that the dose of MSCs
that can be codelivered and colocalized at the site of individ-
ual islet engraftment by forming MSC islet composites is too
low to promote early and robust improvements in graft func-
tion at the clinically preferred intraportal site. Lack of effi-
cacy due to the low MSC dose will be further exacerbated
by the loss of up to 90% of MSCs posttransplantation.3
These findings are of significant clinical importance because
they highlight the need to interpret some of the promising ex-
perimental studies using extrahepatic sites with caution, in
terms of translation to clinical practice. We propose that
MSC cotransplantation strategies present superior transla-
tional benefit at alternative sites, such as the intramuscular
site, where codelivery of therapeutically efficacious MSC
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doses can more likely be achieved. However, the issue of lim-
ited MSC survival and functional persistence in vivo remains
a significant issue at these sites. Emerging evidence indicates
tremendous potential in harnessing the MSC secretome as a
“cell-free” regenerative strategy in numerous disease settings,
including diabetes.5 The use of defined MSC biotherapeutics
has obvious translational advantage, negating many safety
and regulatory concerns of incorporating MSCs into clinical
transplantation protocols. Because it is not possible to deliver
high numbers of MSCs directly with the islets intraportally,
alternative MSC-based strategies using defined dosing
schedules of MSC-derived trophic factors5 may provide a
preferable approach to improve the outcomes of intraportal
islet transplantation.
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FIGURE 1. Seventy-five mouse islets were precultured with 200 000 fluorescently labeled (Qtracker 525 cell labeling kit; Invitrogen) mouse
MSCs (green), per 35-mm dish, in suspension coculture for 24 hours to form composite MSC-islets. A single islet (white arrow) surrounded
by MSCs (green) at the beginning of the coculture period (A). MSCs adhere to the edge of the islet after 2 hours of culture (B) and MSCs
penetrate the islet core after 8 hours, leading to the formation of MSC-islet composites. Scale bar 100 μm. C, Insulin release at 2 and
20 mmol/L glucose of 10 replicates of 3 islets per Eppendorf tube, precultured alone (black bar) for 24 hours, or in suspension coculture
with 20 000 (dotted bar), or 200 000 MSCs (white bar), to formMSC-islet composites, *P < 0.01 versus islets precultured alone at the same
glucose concentration. D. Average blood glucose concentrations of mice receiving intraportal transplantations of 200 islets precultured with
MSCs (at a ratio of 75 islets: 200 000MSCs per 35-mm dish) in suspension coculture for 24 hours to form composites (dashed line) or islets
precultured alone for 24 hours (solid line), *P < 0.05 vs. mice transplanted with MSC islet composites (repeated-measures ANOVA with
Bonferroni post hoc test, n = 6 for both transplant groups). ANOVA, analysis of variance.
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